SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is facing downward pressure, with community members debating whether it's losing ground to gold as a safe haven asset. Speculation is swirling around a potential announcement and its possible impact, while others point to technical charts suggesting further declines. Community members are also discussing the potential impact of macro events on Bitcoin's price.

SPDR Gold Trust - SPDR Gold Shares ETF

SPDR Gold Shares ETF

SPDR Gold Shares ETF ($GLD) is trending as gold prices reach new highs, driven by trade tensions and expectations of future rate cuts. The community is actively discussing whether this rally is sustainable or if a significant correction is on the horizon, with some seeing bubble-like conditions. Some traders point to potential factors that could either continue to fuel the run or trigger a pullback.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors discuss the potential impact of China's tightening battery export rules, which could favor the company's U.S.-based solid-state technology; the community is actively debating the stock's recent price action, with some seeing it as a buying opportunity while others express concerns about a possible pullback, also earnings are upcoming with investors hoping to see revenue.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending as traders assess potential downside risk amid geopolitical tensions and anticipation of an upcoming announcement. Community members are weighing the possibility of a sharp reversal against concerns of deeper losses, with focus on key support levels. Discussions also involve broader market factors like bank performance and potential impacts from a former president's comments.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community debates the stock's valuation and potential catalysts, including Trump's involvement and the company's Bitcoin holdings. Discussions also involve the broader implications of tariffs and government spending. Concerns about dilution and the company's financial performance are prominent talking points.

Aptera Motors Corp - Ordinary Shares - Class B

Aptera Motors Corp

Aptera Motors ($SEV) is trending due to its volatile Nasdaq debut, marked by multiple trading halts and a wide price range. The community is actively discussing entry points, potential shorting activity, and the company's long-term prospects in the solar EV market. Despite the initial turbulence, some investors remain optimistic about Aptera's technology and future potential.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

UVIX is trending as traders hedge against market uncertainty, with community members discussing potential upside driven by geopolitical tensions and economic data. Some are debating whether the recent moves signal a larger correction, while others are looking to profit from short-term volatility. The fund's movements are being closely watched amid broader concerns about market valuations and the potential impact of a government shutdown.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kenvue is trending due to legal challenges in the UK concerning talc-related cancer claims, sparking a sell-off despite the company's denial of the allegations. Community discussions revolve around the potential liability for Kenvue versus J&J, the extent of the overreaction, and whether this presents a buying opportunity given the company's dividend and well-known brands. Some traders are looking at short-term call options, while others are considering longer-term positions based on value and potential bounce-back.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

GDX is surging, with community members pointing to gold's breakout and potential for further gains as reasons to buy calls. Some are wary of overbought conditions and potential pullbacks, while others are taking profits and eyeing short positions. The broader context includes discussion of central bank policy, economic uncertainty, and gold's role as a safe haven.

Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. It focuses on two proprietary platforms: Cerebrum and Solidus. The Cerebrum platform utilizes a deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies. The Solidus platform consists of antisense oligonucleotide, or ASO. The company was founded by Kiran Reddy, David Goldstein, and Steven Petrou on September 22, 2015 and is headquartered in Boston, MA.

Praxis Precision Medicines Inc

PRAX is trending as traders discuss its recent surge following positive Phase 3 trial results for its essential tremor treatment, with analysts issuing bullish price targets. Community chatter revolves around short squeezes, potential profit-taking, and whether the company will pursue a dilutive offering. The stock is also being mentioned in the context of other bio stocks experiencing similar momentum.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Janux Therapeutics (JANX) Surges 6.8%: Is This an Indication of Further Gains?

Janux Therapeutics (JANX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB) today...

Stoke Therapeutics (STOK) Surges 11.7%: Is This an Indication of Further Gains?

Stoke Therapeutics (STOK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates

Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jefferies starts Stoke at Buy, sees $1 bln+ opportunity in rare epilepsy drug

Investing.com -- Jefferies initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating given a better risk-reward profile ahead of late-stage data for its lead drug candidate targeting Dravet syndrome, a severe and rare form of childhood epilepsy.

Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet

Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates

Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential

Wall Street expects both of these biotech stocks to soar over 200% in the next 12 months.

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.

Stoke Therapeutics Inc

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

STOK
Stoke Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest STOK News

STOKStoke Therapeutics Inc